Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3966847 | 0.94 | MDM2 (0.81) | MDM2TP53EPHX2KDM4EL3MBTL1 | |
| SCHEMBL8248075 | 0.93 | MDM2 (0.76) | MDM2TP53EPHX2CHRM2CHRM3 | |
| SCHEMBL3964590 | 0.90 | MDM2 (0.82) | MDM2TP53KDM4ECHRM2CHRM3 | |
| SCHEMBL3968122 | 0.89 | MDM2 (0.80) | MDM2TP53CNR1CNR2 | |
| SCHEMBL3970646 | 0.88 | MDM2 (0.79) | MDM2TP53L3MBTL1 | |
| SCHEMBL27705451 | 0.88 | MDM2 (0.69) | MDM2TP53EPHX2L3MBTL1CXCR3 | |
| SCHEMBL3971402 | 0.87 | MDM2 (1.00) | MDM2TP53LMNAKDM4EL3MBTL1 | |
| SCHEMBL3964720 | 0.87 | MDM2 (0.86) | MDM2TP53CHRM2CHRM3L3MBTL1 | |
| SCHEMBL8249405 | 0.87 | TP53 (0.77) | MDM2TP53LMNAEPHX2KDM4E | |
| SCHEMBL8249668 | 0.87 | MDM2 (0.77) | MDM2TP53LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203489-B | Oxindole derivatives | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | claimed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | claimed |
| JP-2008543917-A | — | — | 2008-12-04 | — | — | JP | claimed |
| CN-101203489-A | Oxindole derivatives | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | claimed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | claimed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | claimed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | claimed |
| CN-101203489-B | Oxindole derivatives | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576082-B2 | Oxindole derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| CN-101203489-A | Oxindole derivatives | HOFFMANN LA ROCHE (CH) | 2008-06-18 | — | — | CN | disclosed |
| EP-1896412-A2 | OXINDOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136606-A2 | OXINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293319-A1 | Oxindole derivatives | LUK KIM-CHUN | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293319-A1 | Oxindole derivatives | CCNI, OGFR, MKI67 | MDM2 759/4885TP53 96/4885CNR1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.